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Duplex scan surveillance after carotid angioplasty
and stenting: A rational definition of stent stenosis
Paul A. Armstrong, DO,a Dennis F. Bandyk, MD,a Brad L. Johnson, MD,a Murray L. Shames, MD,a
Bruce R. Zwiebel, MD,b and Martin R. Back, MDa Tampa, Fla
Objective: A duplex ultrasound (DUS) surveillance algorithm used after carotid endarterectomy (CEA) was applied to
patients after carotid stenting and angioplasty (CAS) to determine the incidence of high-grade stent stenosis, its
relationship to clinical symptoms, and the outcome of reintervention.
Methods: In 111 patients who underwent 114 CAS procedures for symptomatic (n  62) or asymptomatic (n  52)
atherosclerotic or recurrent stenosis after CEA involving the internal carotid artery (ICA), DUS surveillance was
performed <30 days and every 6 months thereafter. High-grade stenosis (peak systolic velocity [PSV] >300 cm/s,
diastolic velocity >125 cm/s, internal carotid artery stent/proximal common carotid artery ratio >4) involving the
stented arterial segment prompted diagnostic angiography and repair when >75% diameter-reduction stenosis was
confirmed. Criteria for >50% CAS stenosis was a PSV >150 cm/s with a PSV stent ratio >2.
Results: All 114 carotid stents were patent on initial DUS imaging, including 90 (79%) with PSV <150 cm/s (94  24
cm/s), 23 (20%) with PSV >150 cm/s (183  34 cm/s), and one with high-grade, residual stenosis (PSV  355).
During subsequent surveillance, 81 CAS sites (71%) exhibited no change in stenosis severity, nine sites demonstrated
stenosis regression to <50% diameter reduction, and five sites developed velocity spectra of a high-grade stenosis.
Angiography confirmed >75% diameter reduction in all six CASs with DUS-detected high-grade stenosis, all patients
were asymptomatic, and treatment consisted of endovascular (n 5) or surgical (n 1) repair. During the mean 33-month
follow-up period, three patients experienced ipsilateral, reversible neurologic events at 30, 45, and 120 days after CAS; none
was associated with severe stent stenosis. No stent occlusions occurred, and no patient with>50% CAS stenosis on initial or
subsequent testing developed a permanent ipsilateral permanent neurologic deficit or stroke-related death.
Conclusion: DUS surveillance after CAS identified a 5% procedural failure rate due to the development of high-grade
in-stent stenosis. Both progression and regression of stent stenosis severity was observed on serial testing, but 70% of CAS
sites demonstrated velocity spectra consistent with<50% diameter reduction. The surveillance algorithm used, including
reintervention for asymptomatic high-grade CAS stenosis, was associated with stent patency and the absence of disabling
stroke. (J Vasc Surg 2007;46:460-6.)As the clinical application of carotid artery stenting and
angioplasty (CAS) for severe internal carotid artery (ICA)
stenosis expands, its durability and effectiveness for stroke
prevention continues to be evaluated. The incidence and
severity of in-stent stenosis remains a concern, with rates of
1% to 50% being reported; the wide range attributed to
variations in diagnostic testing methods, interpretation cri-
teria, and duration of follow-up.1-5 At present, it is recom-
mended that each vascular center performing CAS conduct
surveillance for stent failure and correlate its occurrence
with clinical neurologic events and stroke-related death.
The accuracy of duplex ultrasound (DUS) imaging in
grading CAS site stenosis has been questioned, especially in
identifying the moderate 50% diameter-reduction (DR)
threshold. Correlation with procedural CAS angiography
shows 20% to 30% of ICA stents with 50% DR on
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460angiography have peak systolic velocity (PSV) spectra of
150 to 200 cm/s on the initial DUS examination.6-8 The
clinical significance of elevated stent velocity after CAS is
unknown, as is the significance of moderate 50% to 75%
in-stent stenosis. After surgical endarterectomy (CEA), re-
stenosis of this severity has not been associated with an
increased risk for stroke compared with normal (50%DR)
repairs. However, high-grade (75% to 80% DR) stenosis
after CEA or CAS is generally thought to be a clinically
significant lesion and has been associated with progression
to occlusion and stroke.1,2,9
Most reports onCAS surveillance have not focused on the
detection and treatment of high-grade stent stenosis or rec-
ommended a clinically useful algorithm for patient
follow-up. This article details our experience using a
previously validated surveillance protocol after CEA and
applied for CAS surveillance.9 The natural history of
carotid stent stenosis was studied by serial DUS testing,
including assessment for stent stenosis progression or
regression, with attention to the yield of surveillance for
detecting of high-grade in-stent stenosis and its relation-
ship to clinical symptoms.
METHODS
Patients. A total of 111 patients (93 men, 18 women)
with a mean age of 64 years (range, 54 to 83 years)
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or asymptomatic (n  52) carotid occlusive disease. Of
these, 86 patients (75%) had treatment of severe ICA
atherosclerotic stenosis, 28 were treated for 75% DR
recurrent stenosis after CEA, and three had staged CAS
procedures for bilateral 75% DR CEA-site stenosis:
Eligibility for CAS was determined by Centers for
Medicare & Medicaid Services (CMS) guidelines for CAS
coverage, including voluntary randomization in on-going
multicenter clinical CAS trials and high-risk operative pa-
tients.10 Eighteen patients were enrolled in the Carotid
Revascularization Endarterectomy versus Stent Trial
(CREST), one patient in the Acculink for Revascularization
of Carotids in High-Risk Patients Trial (ARCHeR), and
the remaining 92 patients were judged to be high-risk for
CEA (neck irradiation, prior CEA, severe cardiac/pulmo-
nary disease) and had aortic arch and ICA anatomy suitable
for CAS (Table I).
Patients who underwent CAS but did not complete the
minimum 12-month protocol of DUS surveillance were
excluded from review.
Carotid stent-angioplasty procedure. Patients eligi-
ble for enrollment in investigational trials were random-
ized, treated, and followed up according to each specific
trial protocol. In all 19 clinical trial patients, the CAS
procedure was performed using an embolic protection de-
vice (EPD) and insertion of an Accunet/Acculink Carotid
Stent System (Guidant, St. Paul, Minn). An additional 13
high-risk patients had Acculink carotid stents placed. Three
patients had EPD using the Accunet filter and Precise stents
(Johnson & Johnson, Miami, Fla) were implanted. The
remaining 79 high-risk patients had EPD/CAS using
the EZ Filter Wire /Wallstent system (Boston Scientific,
Natick, Mass).
Preprocedure antiplatelet therapy using clopidogrel
(75mg/day) and aspirin (325 mg/day) was started 3 days
before the procedure and continued after CAS.
The procedure was performed through femoral artery
access, and a 6F or 7F 90-cm shuttle catheter sheath was
guided into the common carotid artery. At the time of
aortic arch access, heparin (100 U/kg) was administered,
and activated clotting time (ACT) was monitored to ensure
a value 250 seconds. With the shuttle platform in place,
the ICA lesion was traversed with a 0.014-inch filter wire
and the EPD was deployed. Balloon dilation of the lesion
before stent deployment was performed in 76 cases (67%).
Stenosis and vessel measurements were calculated
according to North American Symptomatic Carotid
Endarterectomy Trial (NASCET) criteria (minimal lu-
men diameter compared to normal distal ICA diameter)
and appropriate size stents were deployed. Balloon dilation
after stenting was performed using 4.5-mm to 6.0-mm
diameter 2-cm length balloons. Completion carotid and
cerebral angiograms with lateral and anteroposterior views
were obtained, and a residual stenosis of 20% was ac-
cepted as a technically satisfactory procedure. No heparin
reversal was performed.Surveillance after carotid angioplasty and stenting.
All patients undergoing CAS procedures were evaluated
1 month of the procedure, with most having a carotid
DUS scan both before discharge and at 1 month after CAS.
Carotid testing was performed in an accredited (Interso-
cietal Commission on Accreditation of Vascular Labora-
tories) testing facility. A 60° Doppler angle of insonation
was used when possible to record midstream velocity
spectra (PSV, end-diastolic velocity [EDV]) from the
common carotid artery (CCA), along the stent length,
and in the ICA distal to the stent. Power Doppler
imaging of the stent and adjacent artery segments was
performed to assess caliber and sites of maximum steno-
sis. The highest PSV value recorded from the stent was
used with the proximal CCA value to calculate the
ICAstent/CCA PSV ratio, or proximal stent PSV to cal-
culate the PSVStent ratio with a value 2 indicating
stenosis. B-mode imaging was also used to record trans-
verse and anteroposterior stent diameters in the proxi-
mal, middle, and distal stent regions. Interpretation
criteria used to estimate stenosis severity after CAS clas-
sified stenosis into four categories: 50% DR, 50% to
75% DR,  75% DR, and occlusion (Table II).
DUS surveillance was performed at 6-month intervals
after the initial 1-month evaluation. A shorter 3-month
interval between scans was performed in patients with
50% DR residual stenosis and when stent stenosis pro-
gression from50% DR to50% DR was detected, and if
no further progression occurred, the surveillance interval
was increased to 6 months. When high-grade,75% veloc-
ity spectra were identified, angiographic imaging was rec-
ommended with consideration for intervention if a high-
Table I. Medical and anatomic conditions in 92 patents
judged to be high-risk for surgical carotid endarterectomy
Variables Patients (n)
Medical comorbidities
Cardiac disease 31
Ischemic cardiomyopathy* 12
Angina† 12
Cardiac surgery‡ 4
Recent MI (30 days) 3
COPD 10
Oxygen-dependent 6
Steroid-dependent 2
FEV1 30% 2
Anatomic conditions 57
Prior ipsilateral CEA 28
Prior neck irradiation 11
High cervical ICA lesion 10
Contralateral ICA occlusion 8
Prior radical neck dissection 1
Tracheostomy 1
COPD, Chronic obstructive pulmonary disease; FEV1, Forced expiratory
volume in 1 second; CEA, carotid endarterectomy; ICA, internal carotid
artery.
*American Heart Association stage III or IV; ejection fraction 30%.
†American Heart Association class III or IV.
‡Anticipated or performed 30 days.grade stent stenosis was confirmed.
locity;
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were performed on the basis of duplex scan findings of
50% DR stent stenosis, or intervention for 75% DR
stenosis. The 2 analysis was used to compare differences in
stenosis progression between patient groups. Continuous
data are expressed as mean  standard deviation (or 
standard error of mean for n 15).
RESULTS
Periprocedural outcomes. No procedural strokes,
death, or stent occlusions occurred. One patient required
intraprocedural thrombolysis for middle cerebral artery
occlusion. Initial duplex testing identified normal (PSV
150 cm/s) velocity spectra at 90 CAS sites (79%) (PSV,
94  24 cm/s; PSV ratio, 1.2  0.3; Fig 1). Velocity
spectra in the 50% to 75% DR category (PSV, 183  34
cm/s; PSV ratio, 2.5  0.5) were recorded from 23 CAS
sites (20%), and one stent had a PSV of 355 cm/s and an
EDV of 126 cm/s, indicating a high-grade residual
stenosis. This patient had been treated for an asymptom-
atic 85% DR CEA-site stenosis, and balloon angioplasty
was not performed after stent deployment owing to
difficult aortic arch anatomy and loss of CCA catheter
access. A completion angiogram demonstrated a 30%
residual stent stenosis. A follow-up DUS scan at 4
months documented asymptomatic stenosis progression
(PSV, 550 cm/s; EDV, 200 cm/s; PSV ratio, 11) and
surgical repair with stent explant and vein patch angio-
plasty was performed 5 months after CAS.
Carotid stent surveillance. During the mean 33-
month follow-up period (range, 12 to 78 months), three
patients experienced ipsilateral, nondisabling, reversible
neurologic events at 30, 45, and 120 days after CAS; none
was associated with severe stent stenosis (50% DR in 2;
50% to 75% DR in 1) or cerebral infarction on computed
tomography or magnetic resonance imaging.
Compared with the initial DUS testing, serial scans
detected progressive CAS stenosis from 50% DR (PSV,
97  25 cm/s) to 50% to 75% DR (PSV, 217  38 cm/s)
at 21 (23%) of 90 sites, including three sites (4%) that
subsequently progressed to 75% DR in-stent stenosis
(Table III). Velocity spectra indicating stenosis regression
or progression was recorded from 23 CAS sites with 50% to
75% DR stenosis on initial scanning, including nine sites
with stenosis regression from 50% to 75% DR (PSV, 195
42 cm/s) to 50% DR (PSV, 115  13 cm/s), and two
Table II. University of South Florida duplex ultrasound s
Stenosis category (DR) PSV (cm/s) PSV ratio
50% (none) 150 2
50%-75% (moderate) 150 2
75% (severe) 300 4
Occlusion NA NA
DR, Diameter reduction; PSV, peak systolic velocity; EDV, end diastolic vesites with progression to 75% DR in-stent stenosis. Themean time of CAS site regression (n 9) was 9 6months
compared with 14  10 months for stenosis progression
(n 23). Of note, stent stenosis that developed after initial
normal (50% DR category) DUS testing was not ob-
served to regress on subsequent scans.
By life-table analysis, freedom from DUS-detected
50% DR stenosis was 79% at 1 month, 78% at 6 months,
76% at 1 year, and 67% at 4 years, and freedom from75%
DR stenosis was 97% at 1 year and 95% at 4 years (Fig 2).
No stent occlusion was identified. The risk for developing a
persistent 50% DR stent stenosis was similar after treat-
ment for CEA-site stenosis (9 [32%] of 28), atherosclerotic
ICA stenosis in an irradiated neck (3 [33%] of 9), and ICA
stenosis in a nonirradiated neck (23 [31%] of 75).
The yield of DUS surveillance for detection of high-
grade CAS stenosis (PSV, 437  98 cm/s [range, 301 to
578 cm/s]; EDV, 167  29 cm/s [range, 126 to 201
cm/s]) was 5% (6/114 CAS); all associated with asymp-
tomatic stenosis progression. Diagnostic biplane angiogra-
phy confirmed a 75% DR in-stent stenosis in all six
patients with DUS-detected high-grade CAS stenosis. The
angiographic findings resulted in reinterventions consisting
of balloon angioplasty (n 3), stent angioplasty (n 2), or
Fig 1. Classification by percentage of diameter reduction (DR)
of carotid stent stenosis at 1month, and 1 year, maximumdiameter
reduction during surveillance, and diameter reduction at the time
of last follow-up, including intervention for 75% DR. CAS,
carotid angioplasty and stenting.
riteria for grading carotid stent stenosis
V (cm/s) Color/power Doppler scan imaging results
NA No or minimal stent lumen reduction
125 Turbulent flow, stent lumen reduction present
125 High-grade stent stenosis, damping of distal
ICA spectral waveform
NA No stent flow visualized
NA, not applicable.can c
EDsurgical repair (n  1). DUS testing after reintervention
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181 cm/s; EDV, 87 cm/s) after balloon angioplasty in one
patient. No further stenosis progression has been observed
to date in this group.
Beyond 30 days, no patient with 50% DR stent
stenosis on initial testing or subsequent DUS surveil-
lance developed ipsilateral stroke. Six patients died dur-
ing follow-up of cardiovascular or pulmonary disease.
Contralateral internal carotid artery stenosis
progression. The status of the 108 contralateral non-
stented ICAs at the initial post-CAS scan included occlu-
sion (n 8), 50% to 75% DR stenosis (n 19), and50%
DR stenosis (n  81). Five patients with 50% to 75% DR
ICA stenosis progressed to 75% DR without symptoms
and underwent CEA.
DISCUSSION
The efficacy of CAS for stroke prevention is currently
under investigation in the National Institutes of Health
sponsored, multicenter, randomized CREST clinical trial.
The completed Stenting and Angioplasty with Protection
in Patients at High Risk for Endarterectomy (SAPPHIRE)
Table III. Summary of cohort carotid stent surveillance: i
diameter reduction
DR
Initial study, n (%)
(n114)
No change
DR on last
study, n (%)
50% 90 (78.9) 69 (60.5)
50% 23 (20.2) 12 (10.5)
75% 1 (0.9) 1 (0.9)
DR, Diameter reduction; NA, not applicable.
Reintervention: radiation atherosclerosis (n  2), recurrent carotid endarte
*Mean time to progression of carotid artery stent stenosis 14  10 months
†Mean time to regression of carotid artery stent stenosis 9  7 months.
Fig 2. Freedom from carotid stent stenosis of 50% (triangles)
or 75% (squares) diameter reduction (DR) based on duplex
ultrasound surveillance using life-table analysis.clinical trial, which compared outcomes between CEA andCAS with embolic protection in high-risk patients, found
equivalent stroke rates, but the incidence of reintervention
was higher (P  .04) after CEA (4.3%) than after CAS
(0.6%).11 For CAS to demonstrate equivalent stroke pre-
vention compared with medical management or CEA, low
procedural morbidity (stroke, death) coupled with durabil-
ity and a low incidence of restenosis requiring reinterven-
tion will need to be achieved.
Our vascular group has recommended a policy of DUS
surveillance after carotid repair and reoperation when high-
grade stenosis is identified.9 Patient outcomes after CEA
and now CAS interventions have shown the yield of DUS
surveillance to be similar: 5.9% intervention rate after CEA
primarily for treatment of contralateral ICA disease pro-
gression compared with 10% after CAS with an equivalent
intervention rate for high-grade CAS stenosis (5%) or con-
tralateral ICA stenosis (5%). After surgical or endovascular
carotid intervention, stenosis progression typically oc-
curred without the appearance of neurologic events. Inter-
vention for asymptomatic high-grade stenosis (75% to
80%) was accomplished successfully with minimal proce-
dural morbidity and was associated with low long-term
stroke rates of1% per year. After CAS, progression of ICA
stent stenosis was 2.5 times more common (24 sites vs 9
sites) than regression and typically occurred 6 months of
the procedure (mean, 14 months).9 Carotid occlusion was
not observed after CEA or CAS partly because intervention
for high-grade stenosis was performed.
Criteria for the interpretation DUS-detected stenosis
after CAS are in evolution, including defining the threshold
for reintervention. Moderate stenosis (50% DR) involv-
ing the CAS repaired was detected in approximately 20%
patients on initial testing and during surveillance. This
incidence of moderate stenosis is similar to other reports
using similar velocity spectra criteria, including Zhou et al12
(16% with ICAstent/CCA 3.2) and Lal et al
8 (20% with
PSV 150 cm/s, ICAstent/CCA 2.2).
The development of high-grade CAS stenosis is of
concern because further progression may lead to occlusion
and stroke. To date, most reports on high-grade stenosis of
70% have found the patients to be asymptomatic, and the
need for reangioplasty or a more complicated surgical by-
pass or repair is controversial.12 Our criteria for 75%
and last recorded duplex study according to in-stent
egression of
AS stenosis,
n (%)
Progression
to 50% DR,
n (%)
Progression to
high-grade stenosis,
n (%)
NA 18* (15.8) 3* (2.6)
9† (7.9) NA 2* (1.8)
0 NA NA
y stenosis (n  1), primary atherosclerotic stenosis (n  2).nitial
R
C
rectomin-stent stenosis includes the combined velocity spectra
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but the clinical decision to proceed with reintervention
should be based on angiographic verification of stenosis
severity, anatomic features of the lesions, patient symp-
toms, patency status of the contralateral ICA, and the
anatomy of the circle of Willis—all factors influencing the
risk vs benefit for reintervention.
Because no patient in our series developed a symptom-
atic high-grade stenosis, the decision to proceed with an
endovascular or surgical repair was made on duplex find-
ings of progressive in-stent stenosis, its verification by arte-
riography, and a perceived risk that progression could result
in stroke. Endovascular intervention for high-grade stent
stenosis was successful in restoring functional patency and
was associated with a low incidence of recurrence. Repeat
intervention may be higher in patients initially treated for
CEA-site stenosis, but this risk factor was not found in our
patient series.12,13 An EDV threshold velocity 125 to
140 cm/s together with color/power Doppler imaging
criteria of severe 2 mm lumen reduction appear to accu-
rately predict a 75% to 80% DR stent stenosis.
DUS scanning can readily image carotid bifurcation
stents, and serial testing can identify stent-related abnor-
malities, including thrombosis, in-stent stenosis, stent de-
formity, lack of apposition to artery wall, and migration.
Stent deployment alters wall compliance of the covered
carotid artery segment, producing a stiffer conduit and,
theoretically, an increase in PSV in the stent, but the PSV
ratio along the stent length should be 2. Blood flow
patterns within a nonstenotic stent are nondisturbed except
at proximal and distal stent orifices where diameter/com-
pliance mismatch is present. Stent structure should contact
the artery wall and plaque, because the incidence of stent
failure and migration is higher when ultrasound imaging
demonstrates poor wall apposition.
Serial ultrasound imaging has shown that both positive
(stent expansion) and negative (stent lumen reduction due
to myointimal hyperplasia) remodeling of the treated ste-
notic ICA occurs.14 The self-expanding stent diameter
increased for several months after deployment, most evi-
dent in the middle stent region, but was negated by the
presence of calcified plaque. In-stent neointimal thickening
is a common finding, and its thickness increases for up to 12
months and usually stabilizes thereafter.
Thus, serial DUS testing with velocity spectra record-
ings indicating stent stenosis regression or progression is
not surprising. A carefully conducted study from the vas-
cular group in Vienna, Austria found the arterial remodel-
ing after CAS most commonly produced a PSV increase
indicating a dominance of negative remodeling secondary
to myointimal proliferation.14 Progression of in-stent ste-
nosis requiring intervention was uncommon (3.4%) using
DUS interpretation criteria similar to this study.
When color Doppler imaging of the CAS segment
demonstrates no stent lumen reduction, a maximum PSV
150 cm/s, and PSVstent ratio 2, assignment to 50%
DR disease category is appropriate. These DUS findings
indicate a nonstenotic or minimally stenotic ICA segmentand are associated with a low subsequent risk for occlusion
or stroke. Data from the CREST core DUS reading center
found that 85% of initial DUS studies had a PSV 125
cm/s and 93% had a PSV 150 cm/s. In our experience,
approximately three quarters of CAS sites were in this
category initially and throughout the 3-year surveillance
period. For patent CAS sites with PSV 150 cm/s,
PSVstent ratio2, two stenosis severity categories of 50% to
75% DR and75% DR are useful to track stenosis progres-
sion or regression, with the 75% DR category indicating
high-grade stenosis and signaling the threshold for addi-
tional patient evaluation including possible intervention.
One limitation of this review was the absence of struc-
tured angiographic verification of DR and stent stenosis.
Although omitted in this study, angiographic verifications
have previously confirmed the utility of DUS for predicting
recurrent stenosis and failing vascular interventions in a
variety of vascular beds. Routine angiography in asymp-
tomatic patients with minimal or moderate restenosis is
difficult to justify in a review of this type, especially because
only asymptomatic high-grade (75%) carotid occlusive
disease is thought to be clinically significant. Our experi-
ence and other published reports support these DUS inter-
pretation criteria of moderate and high-grade stent steno-
sis. An in-stent stenosis with severe hemodynamic
abnormalities (PSV 300, EDV 125 to 140 cm/s, and
PSVstent ratio4) is likely to have75% DR lumen reduc-
tion on angiographic imaging.
Clearly, DUS scanning is an accurate modality for
identifying stent stenosis but does the traditional label of
DUS overestimation of stenosis apply to CAS surveillance?
The diagnostic acumen for carotid DUS imaging is highest
in confirming the minimal (50%) diameter reduction,
stent patency or stent occlusion; however, stents demon-
strating findings of intimal hyperplasia on power Doppler
imaging or 50% to 75% diameter reduction by velocity
criteria may represent a group that may be prone to pro-
gression of in-stent stenosis. Therefore, grading 50%
stent stenosis may be prone to overestimation error, and
confirmatory imaging with angiography should be consid-
ered if carotid reintervention is deemed gainful for symp-
tomatic or asymptomatic patients.
Overestimation of high-grade stent stenosis was not a
common event in this series. Both asymptomatic patients
with DUS studies demonstrating 75% stent stenosis and
symptomatic patients after CAS had diagnostic imaging
studies that verified DUS findings to be accurate in direct-
ing the need for carotid reintervention. As a result of this
review, we rely on DUS surveillance to provide a safe and
effective noninvasive diagnostic tool to predict high-grade
restenosis after CAS, allowing us to limit unnecessary ex-
posure to radiation and contrast mediums in patients who
are not likely to benefit from carotid reintervention.
Testing intervals of 6 months are sufficient to detect
CAS site stenosis and monitor 50% to 75% stenotic lesions
for progression. However, surveillance is also important to
detect contralateral ICA stenosis progression. Imaging the
CAS site 1 month is useful to exclude residual stenosis
JOURNAL OF VASCULAR SURGERY
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testing confirms 50% ICA stenosis bilateral beyond the
first 18 months, an annual scan is adequate for disease
monitoring. Surveillance every 6 months is recommended
in patients with 50% DR ipsilateral or contralateral ICA
stenosis. The development of hemispheric symptoms in the
presence of50% DR ICA or CAS stenosis, or asymptom-
atic disease progression to a high-grade stenosis (75% to
80% DR, EDV 140 cm/s), should prompt a recommen-
dation of surgical or endovascular (stent-assisted angio-
plasty) intervention in appropriate patients.
CONCLUSION
DUS surveillance after CAS identified a 5% procedural
failure rate due to the development of high-grade in-stent
stenosis, a higher clinical yield than CEA surveillance. Both
progression and regression of stent stenosis severity was
observed on serial testing, but 70% of CAS sites demon-
strated velocity spectra consistent with 50% DR. Con-
tralateral disease progression remains a risk factor, with a 5%
intervention rate after both CEA and CAS using similar
velocity spectra criteria indicating 75% DR stenosis. Our
policy of DUS surveillance and reintervention for high-
grade stenosis was associated with sustained stent patency
and infrequent neurologic events.
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Dr Ali F. AbuRahma (Charleston, WV). Carotid artery
stenting has become an accepted treatment modality for carotid
stenosis, particularly in high-risk patients. However, there is an
ongoing debate regarding which duplex ultrasound criteria to use
to determine the rate of in-stent restenosis. This study is by Dr
Armstrong and his group, and they are well respected and nation-
ally known for their advocacy for duplex scan surveillance after
vascular interventions. This study reports on duplex scan surveil-
lance after carotid artery stenting and the rationale for the defini-
tion of in-stent restenosis.
In this study, Dr Armstrong and his group analyzed their
experience using a previously validated surveillance protocol after
carotid endarterectomy and applied these criteria to carotid artery
stenting surveillance. In a similar study that we presented at the
Eastern Vascular Society meeting in Washington, DC in Septem-
ber 2006, which is presently in press, when we applied the old
duplex ultrasound velocity criteria for nonstented carotid arteries,nosis, as defined by a peak systolic velocity of 120 cm/s, how-
ever, when we applied new duplex ultrasound criteria for stented
arteries, a peak systolic velocity of155 cm/s was consistent with
30% restenosis in only 33% of patients at a mean follow-up of 2
years.
With this in mind, I have the following questions and/or
comments for Dr. Armstrong.
First, it is noted in your study that you used criteria for carotid
artery stent surveillance that was somewhat similar with some
modification to the criteria your group published in the Journal of
Vascular Surgery in 1999 for carotid endarterectomy surveillance.
Specifically, to define a 50% stenosis category, the peak systolic
velocity was increased from 125 cm/s to 150 cm/s, with an
ICA/CCA ratio of 2; and for 50% to 75% stenosis, the peak
systolic velocity was raised from 125 cm/s to 150 cm/sec, with
a ratio of 2. For stenosis75%, the criteria were left the same (eg,
a peak systolic velocity of300 cm/s with a ratio of4 and an end
diastolic velocity 125 cm/s. Did you validate these criteria on
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obtain any other modality, specifically, carotid angiography or
CTA, to verify the degree of in-stent restenosis? If so, did you
conduct any ROC curves to detect the sensitivity, specificity,
positive and negative predictive values for specific velocities that
were consistent with the various classifications you propose in your
study?
Second, did you obtain immediate duplex ultrasounds after
completion of the carotid stenting to compare normal angiography
after carotid stenting to the peak systolic velocities and/or the end
diastolic velocities?
Third, in your presentation, only six patients were found to
have 75% in-stent restenosis that required intervention. In view
of the earlier discussion, is it possible that there are other patients
who have similar stenoses that were missed because of your present
criteria? It is my understanding that these are the only six patients
who had their stenoses confirmed by arteriography.
I enjoyed your presentation, and I am looking forward to
seeing additional work on this very important clinical subject from
your well-respected institution.Dr Paul A. Armstrong: Certainly one criticism of this review
may be the lack of a structured validation method (ie, angiogra-
phy), but the validation for carotid duplex criteria does have an
established track record, including recent work done by Dr Hob-
son and others. We believe these data to be valid based on the
recent information provided by the core duplex reading center
from the CREST Trial, which documented strongly favorable
positive predictive values for defining moderate and high-grade
lesions using similar duplex criteria.
Our current surveillance protocol includes immediate duplex
scanning the day of the procedure. In addition we are now using
IVUS as part of stent implantation to provide in formation on
vessel diameters, plaque morphology, and stent apposition.
In answer to whether or not we aremissing high-grade lesions,
we would say no. As you are aware, some investigators are support-
ive of accepting higher stent velocities based on the stent charac-
teristics, and in general, we know that there is a tendency of duplex
to overestimate stenosis. Therefore the chance of missing high-
grade asymptomatic lesions when applying similar criteria in an
accredited vascular laboratory is not likely.
